Drug Screening Reveals That Ibrutinib (PCI-32765) Exhibits Synergy With BCL-2 and Proteasome Inhibitors In Models Of Mantle Cell Lymphoma (MCL) and Chronic Lymphocytic Leukemia (CLL)
- Resource Type
- Abstract
- Source
- In
Blood 15 November 2013 122(21):3080-3080 - Subject
- Language
- ISSN
- 0006-4971